Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to assess the clinical activity and safety of INCMGA00012 in participants with advanced/metastatic Merkel cell carcinoma (MCC).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03599713
Study type Interventional
Source Incyte Corporation
Contact
Status Active, not recruiting
Phase Phase 2
Start date February 25, 2019
Completion date June 28, 2024

See also
  Status Clinical Trial Phase
Recruiting NCT04261855 - Targeted Therapy and Avelumab in Merkel Cell Carcinoma Phase 1/Phase 2
Active, not recruiting NCT03816332 - Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers Phase 1
Recruiting NCT05947500 - Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial Phase 2
Recruiting NCT05269381 - Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03304639 - Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma Phase 2
Recruiting NCT05896839 - Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Phase 1/Phase 2
Approved for marketing NCT03089658 - Expanded Access to Avelumab for Treatment of Metastatic Merkel Cell Carcinoma (mMCC)